SARS-CoV-2 - Deferoxamine - Therapeutic Candidates

SARS-CoV-2 - Deferoxamine - Therapeutic Candidates


Deferoxamine (or Desferal) is a linear bacterial siderophore and chelating agent for trivalent cations. Deferoxamine is capable of binding free iron from plasma or cells to form the ferrioxamine complex. Due to its properties, deferoxamine is used as a first-line treatment for iron overload. Desferal is prescribed for various pathologies such as primary hemochromatosis, secondary hemosiderosis, acute martial intoxication, aluminum poisoning.
Deferoxamine has been included in some clinical studies to develop a treatment for COVID-19 caused by the SARS-CoV-2 coronavirus. Indeed, studies have shown that the replication of some RNA viruses, such as HIV-1 or cytomegalovirus, can be influenced by iron. Deferoxamine was able to inhibit viral replication in cells in vitro. For this reason, deferoxamine is being tested as part of the development of a treatment for COVID-19.

Cat#
Description
Size
Price Excl. VAT
HY-B0988-S
 0,5-1mg 
HY-B0988-1mL
 10mM/1mL 
HY-B0988-100mg
 100mg 
HY-B0988-500mg
 500mg 
458230-1mg
 1mg 
458230-500ug
 500ug 
M5558-100mg
 100 mg 
M5558-500mg
 500 mg 
S1637-100mg
 100mg 
B802717-5mg
 5mg 
B802717-0.5mg
 0.5mg 
B802717-1mg
 1mg 
M5558-10mM
 10 mM/1mL 
B802717-2.5mg
 2.5mg 
T1637-100mg
 100mg 
T1637-200mg
 200mg 
D228980-250mg
 250mg 
D228980-25mg
 25mg 
B6068-100mg
 100 mg 
B6068-500mg
 500 mg 
1883-1000
 1g 
1883-500
 500mg 
445960-1mg
 1mg 
445960-5mg
 5mg 
445961-2,5mg
 2.5mg 
445961-500ug
 500ug 
S1637-200mg
 200mg 
C-2284-500mg
 500 mg 
Number of results per page : 10 50 250